Evidence map›Paper›PMID 41473983›Full record

ArticleChinese medical journal2026

Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries.

Hao Gu, Ruofan Wang, Narasimha M Beeraka, Pengwei Lu, Xiang Zhao, Lianghui Li, Yuqi Liu, Dilipkumar Reddy Kandula, Ruitai Fan, Thainala Gayathri and 4 more

Abstract read
In one paragraph

Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Early- versus late-onset mortality trends in breast and female genital cancers in Spain, 1999-2024.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cancer management and research · 2026
    Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hao GuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.
Ruofan WangDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.
Narasimha M BeerakaDepartment of Human Anatomy and Histology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia.
Pengwei LuDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.
Xiang ZhaoDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.
Lianghui LiDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.
Yuqi LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.
Dilipkumar Reddy KandulaDepartment of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Rajasthan 333010, India.
Ruitai FanDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.
Thainala GayathriNRI Institute of Medical Sciences, Visakhapatnam, Andhra Pradesh 531163, India.
Vladimir N NikolenkoDepartment of Human Anatomy and Histology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia.
Allaka NagalakshmiDepartment of Computer Science, St Philomena's College (Autonomous), Mysuru, Karnataka 570015, India.
Basappa BasappaLaboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Mysuru, Karnataka 570006, India.
Junqi LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is the most common malignancy among women, posing major health, social, and economic challenges worldwide. This study analyzed global breast cancer incidence and mortality in 2022 using Global Cancer Observatory (GLOBOCAN) 2022 data and projected the disease burden to 2050.

methodsBreast cancer incidence and mortality were categorized by region and age. Correlations between age-standardized rates (ASRs) and the Human Development Index (HDI) were assessed using Spearman's rank correlation coefficient (ρ). Future burden estimates for 2050 were projected based on current trends.

resultsIn 2022, approximately 2.30 million new breast cancer cases and 666,103 deaths were reported globally. Age-specific patterns of breast cancer incidence and mortality differed across development HDI levels with incidence peaking at ages 45-69 years and mortality at ages 50-≥85 years across HDI levels. The proportion of cases and deaths among women aged ≥50 years relative to those aged ≤49 years increased with HDI, ranging from 79% vs . 21% for incidence and 90% vs . 10% for deaths in very high HDI countries to 51% vs . 49% and 59% vs . 41% in low HDI countries. HDI showed strong positive correlations with age-standardized incidence rates (ρ = 0.773), period incidence rates (ρ = 0.958), and period mortality rates (ρ = 0.907), and a negative correlation with mortality-to-incidence ratios (ρ = -0.817). Projections indicate that by 2050, breast cancer cases may rise to 3.55 million and deaths to 1.14 million if current patterns continue.

conclusionsBreast cancer remains a major global health concern. Strengthening prevention, early detection, and therapeutic strategies is essential to reduce incidence, improve survival, and alleviate its global burden.

Indexed as

Breast NeoplasmsAdultAgedAged, 80 and overFemaleGlobal Burden of DiseaseGlobal HealthHumansIncidenceMiddle Aged2050 projectionsAge-standardized Disability-adjusted life year rateAge-standardized incidenceAge-standardized mortalityBreast cancerGLOBACAN 2022Sociodemographic indices

Identifiers

PMID41473983
PMCPMC12875702

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.